Navigation Links
IMMUNE 3D® Expands Platform into New Disease Areas and Enters into Drug Discovery
Date:5/14/2019

IMMUNE 3D®, a privately held biotechnology company, announced today an expansion of their business strategy beyond immuno-oncology into areas of autoimmunity, fibrosis and skin immunology. In addition, the company will leverage its proprietary, matched autologous human T cell and tumor cell lines for IO discovery efforts.

IMMUNE 3D®’s proprietary platform aims to study factors that affect immune migration under complex physiological conditions. The company utilizes the platform in areas of drug target discovery, characterization, biomarker identification and drug delivery testing.

"The increase in preclinical research and development spending has steered biopharmaceutical companies towards finding cost-effective alternatives beyond traditional in vivo models,” said Vik Subbu, Founder and CEO of IMMUNE 3D®. “This has paved the way for ex vivo platforms such as IMMUNE 3D® to be used across areas of preclinical studies and translational drug development.“

"IMMUNE 3D® provides unique insights into the tumor immune-microenvironment. Importantly, this platform can assess the efficacy of a wide variety of therapeutic approaches beyond immune checkpoints including the evaluation of CAR-T therapies in solid tumors,” said Dr. Tonya Webb, Associate Professor of Microbiology and Immunology, at the University of Maryland, Baltimore and scientific advisor to IMMUNE 3D®.

IMMUNE 3D® aims to build on its extensive know-how and intellectual property to develop proprietary 3D models across broad immune-mediated diseases. The company has profiled targets that facilitate immune migration using its proprietary human T cell and tumor cell lines. These targets have the potential to serve as novel therapies across a variety of human disorders such as cancer, autoimmunity and infectious diseases.

About IMMUNE 3D®
IMMUNE 3D®'s proprietary platform, provides a unique and powerful tool to interrogate immunobiology of diseases. The Company’s mission is to shift the paradigm towards a wider use of 3D cultures in translational research while accelerating much needed drug candidates into the clinic. The company has assembled a network of key opinion leaders, academic partnerships, board members and industry scientists to advance its platform.
http://www.immune3d.com

Read the full story at https://www.prweb.com/releases/immune_3d_expands_platform_into_new_disease_areas_and_enters_into_drug_discovery/prweb16301402.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
2. Trivedi Global, Inc. and Maire Mayne Announce Research Results on the Impact of a Biofield Energy Treated Nutraceutical to Combat Inflammation and Autoimmune Disorders
3. Trivedi Global, Inc. and Dr. William Plikerd Announce Research on Impact of a Biofield Energy Treated Nutraceutical for Decreasing Inflammation and Autoimmune Disorders
4. Trivedi Global, Inc. with Inthirani Arul, Announce Research Results on the Impact of a Biofield Energy Nutraceutical for Reducing Inflammation and Autoimmune Disorders
5. IBM: Your Computer Can Help Scientists Study Connection Between Body Bacteria and Autoimmune Diseases
6. TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials
7. Oncimmune Signs Agreement with Leading Provider of Preventative Health Screenings
8. PNAS: From HIV to cancer, IL-37 regulates immune system
9. House fly genome reveals expanded immune system
10. Scientists question fundamental theory about education of immune police
11. Adolescent exposure to thc may cause immune systems to go up in smoke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2020)... FT. LAUDERDALE, Fla. (PRWEB) , ... April 27, ... ... official launch. The first-of-its-kind category-defining service was started by three teenagers with an ... a change in the world during the time of great need and suffering, ...
(Date:4/26/2020)... NEW YORK (PRWEB) , ... April 23, 2020 , ... ... collaboration with GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes ... lung cells, and would be another potential treatment option for COVID-19. , The efforts ...
(Date:4/22/2020)... ... ... RCH Solutions (RCH ), a global provider of Bio-IT computing expertise for ... as Director of Sales and Business Development. Based out of RCH’s location in Boston, ... across the Northeast. , “We continue to see increased demand for specialized scientific computing ...
Breaking Biology News(10 mins):
(Date:4/26/2020)... ... 23, 2020 , ... Indegene Omnipresence, Inc. announced the launch ... services for use on Microsoft Azure. The customer experience management (CXM) technology allows ... a built-for-purpose customer engagement capability to use in their commercial or medical operations. ...
(Date:4/22/2020)... Hungary and CAMBRIDGE, Mass. (PRWEB) , ... April ... ... in Budapest with US offices in Cambridge, MA, announced today that Omixon’s founder ... led the early commercialisation of Omixon’s flagship product Holotype HLA since 2014 before ...
(Date:4/22/2020)... ... April 21, 2020 , ... Ripple Science ... Many clinical trial teams are working remotely and have paused patient visits, forcing ... researchers continue their research during this uncertain time by giving research teams free ...
(Date:4/7/2020)... Calif. (PRWEB) , ... April 06, 2020 , ... ... their future children, reached 200,000 SneakPeek Early Gender DNA Tests sold in ... SneakPeek was launched as an ecommerce product, where a mom could order her ...
Breaking Biology Technology: